Cutaneous T-cell lymphoma vorinostat |
Low |
August 2023 |
Lymphoma bendamustine and rituximab |
Medium |
February 2024 |
NK T-Cell lymphoma DDGP (dexamethasone ciSplatin gemcitabine pegaspargase)3 |
High |
February 2024 |
NK T-Cell lymphoma SMILE (dexamethasone methotrexate IFOSFamide asparaginase etoposide) |
High |
February 2023 |
NK T-Cell lymphoma modified SMILE (dexamethasone methotrexate iFOSFamide pegaspargase etoposide) |
High |
August 2023 |
Non-Hodgkin lymphoma bendamustine and obinutuzumab |
Medium |
August 2022 |
Non-Hodgkin lymphoma chlorambucil and RITUximab |
Medium |
August 2024 |
Non-Hodgkin lymphoma CHOEP14 (CYCLOPHOSPHamide DOXOrubicin vinCRISTine etoposide prednisolone) |
High |
August 2024 |
Non-Hodgkin lymphoma CHOEP21 (CYCLOPHOSPHamide DOXOrubicin vinCRISTine etoposide prednisolone) |
High |
August 2024 |
Non-Hodgkin Lymphoma CHOP14 (CYCLOPHOSPHamide DOXOrubicin vincristine Prednisolone) |
Medium |
August 2024 |
Non-Hodgkin Lymphoma CHOP21 (CYCLOPHOSPHamide DOXOrubicin vincristine Prednisolone) |
Medium |
August 2024 |
Non-Hodgkin lymphoma DA-R-EPOCH (dose adjusted RITUximab etoposide prednisolone vinCRISTine CYCLOPHOSPHamide DOXOrubicin) |
High |
August 2022 |
Non-Hodgkin lymphoma DHAC (dexamethasone cytarabine cARBOplatin) |
High |
August 2024 |
Non-Hodgkin lymphoma hyper CVAD part A |
High |
August 2022 |
Non-Hodgkin lymphoma hyper CVAD Part B |
High |
August 2022 |
Non-Hodgkin lymphoma ICE (fractionated IFOSFamide cARBOplatin etoposide) |
High |
August 2024 |
Non-Hodgkin lymphoma idelalisib |
Low |
August 2024 |
Non-Hodgkin lymphoma obinutuzumab maintenance |
Low |
August 2022 |
Non-Hodgkin lymphoma O-CHOP21 (obinutuzumab CYCLOPHOSPHamide DOXOrubicin vinCRISTine prednisolone) |
Medium |
August 2022 |
Non-Hodgkin lymphoma O-CVP (obinutuzumab CYCLOPHOSPHamide vinCRISTine prednisolone) |
Medium |
August 2022 |
Non-Hodgkin lymphoma polatuzumab vedotin, bendamustine and rituximab3 |
High |
February 2024 |
Non-Hodgkin lymphoma R-CHOEP14 (RITUximab CYCLOPHOSPHamide DOXOrubicin vinCRISTine etoposide prednisolone) |
High |
August 2024 |
Non-Hodgkin Lymphoma R-CHOP14 (RITUximab CYCLOPHOSPHamide DOXOrubicin vinCRISTine Prednisolone) |
Medium |
February 2026 |
Non-Hodgkin lymphoma R-CHOP21 (RITUximab CYCLOPHOSPHamide DOXOrubicin vinCRISTine Prednisolone) |
Medium |
February 2026 |
Non-Hodgkin Lymphoma R-CVP (RITUximab CYCLOPHOSPHamide vincristine Prednisolone) |
Medium |
August 2024 |
Non-Hodgkin lymphoma R-DHAOx (RITUximab dexamethasone cytarabine oxaliplatin) |
High |
August 2024 |
Non-Hodgkin lymphoma R-DHAP (RITUximab dexamethasone cytarabine cISplatin) |
High |
August 2024 |
Non-Hodgkin lymphoma R-GDP (rituximab gemcitabine dexamethasone ciSplatin) |
Medium |
February 2024 |
Non-Hodgkin lymphoma R-GemOX (RITUximab gemcitabine oxaliplatin) |
Medium |
February 2025 |
Non-Hodgkin lymphoma RICE (RITUximab infusional IFOSFamide cARBOplatin etoposide) |
High |
August 2024 |
Non-Hodgkin lymphoma RITUximab |
Medium |
August 2024 |
Non-Hodgkin lymphoma RITUximab Maintenance |
Medium |
February 2023 |
Non-Hodgkin lymphoma R-MiniCHOP (RITUximab CYCLOPHOSPHamide DOXOrubicin vinCRISTine prednisolone) |
High |
August 2024 |
CNS prophylaxis of DLBCL, R-MTX (Rituximab, Methotrexate, Calcium Folinate)
- SAHCDC Approved non-eviQ protocol CNS prophylaxis of DLBCL, R-MTX MTX protocol (Rituximab, Methotrexate, Calcium Folinate) (PDF 256KB) |
High |
March 2023 |
Pembrolizumab (flat dosing) |
Low |
February 2024 |
Peripheral T-cell lymphoma BV-CHP (brentuximab vedotin CYCLOPHOSPHamide DOXOrubicin prednisolone) |
Medium |
August 2023 |
Peripheral T-cell lymphoma pralatrexate |
Medium |
February 2024 |
Peripheral T-cell lymphoma romidepsin |
Medium |
August 2022 |